



Minutes of the GM Formulary Subgroup meeting

Date: 1st October 2015, 12-2pm

Venue: Pharmacy Seminar Room, Wythenshawe Hospital

Present: Sarah Jacobs, Liz Bailey, Connie Chen, Peter Howarth, Aoidín Cooke, Helen Burgess, Dev Devapriya, Claire Vaughan, Charlotte Skitterall, Monica Mason

Apologies: Ann Harrison, Leigh Lord, Jonathan Peacock

Declarations of interest: None

Item 3 – Previous minutes and actions - The minutes from the September meeting were agreed as accurate.

Action: Submit to GMMMG, thereafter add to website

Item 4a – Revised wording 80/20 rule

SJ updated the group on this piece of work and it was agreed that a draft would be sent to FSG members for comment by email.

Action: SJ to circulate draft changes to FSG for comment by 9th October

Item 4b – Venue for the 2016 FSG meetings

MM explained that the Seminar room in the Education Centre at UHSM had been requested rooms for the 2016 meetings, however confirmation was awaited.

Action: MM to contact CM at UHSM on 12th Oct to confirm room bookings.

Item 4c – Changes to the BNF format

MM updated the FSG on changes to the format of the BNF which had recently been announced and the group discussed how these changes may affect the format of the GM formulary which is based on the BNF format. The new BNF format was not available at the time of the meeting for the FSG to view and it was agreed that the formulary content would remain in its current format until such a time as a change was considered necessary.

MM confirmed that RDTC were currently undertaking housekeeping of all current chapters to check that all RAG symbols were correct, hyperlinks were working etc.).

Action: No further action required at present

Item 5 – Formulary amendments Sept 2015

The FSG reviewed proposed formulary amendments from September and agreed the following:

- A link to the MHRA warning on PPIs and the risk of SCLE be added to chapter 1 of the formulary
- Removal of soluble prednisolone tablets from the formulary as discussed in the Carter Review. The group noted that a liquid preparation will become available in the near future for those patients who are truly unable to swallow

non-soluble tablets, but noted that the majority of patients should be able to swallow the non-soluble tablets and therefore this was the only formulation required to be listed within the formulary.

- Removal of dicycloverine tablets from the formulary, on the basis of cost effectiveness. Section 1.2 now contains mebeverine as first choice agent with alternatives as hyoscine butylbromide, peppermint oil and alverine citrate.
- Colief® will be added to the DNP list due to its poor evidence base.
- Topiramate capsules will be removed from the formulary as they are not considered to be an appropriate use of NHS resources being significantly more expensive than topiramate tablets. They will be added to the grey list but to be reserved for those who are unable to tolerate the liquid.
- Dosulepin will be added to the DNP list due to well-established safety concerns.

The group noted the published NTS recommendations;

- Sipolto® Respimat® recommendation will be considered during the respiratory pathways work which is currently ongoing
- Biologic agents – sequential use in psoriasis was noted but no FSG action was deemed necessary

Action: MM to update formulary with above amendments following approval from GMMMMG

Item 6a – Review of formulary chapters – Chapter 4

SJ presented the final draft of chapter 4 of the GM formulary to the group and explained the changes that had been made following the second consultation. The group commented on the changes made and these changes will be summarised in a changes document which will accompany a final version of the chapter for approval at the October GMMMMG meeting.

CS thanked SJ on behalf of the group for her hard work in completing the review of this chapter; thanks were also extended to the Chief Pharmacists and others for their engagement with this chapter review.

Action: SJ to prepare final draft of chapter 4 for submission to GMMMMG with changes summary paper.

Item 6b – Inhaler review (COPD and asthma pathways)

The FSG considered draft COPD and asthma pathways at the October meeting. MM had added inhaler choices to both pathways based on cost effectiveness of the products, with an aim that these pathways would be opened for GM-wide consultation. However secondary care members within the group expressed concern that the pathways did not provide sufficient information with regards to what should be done within the secondary care, once a patient is referred to the COPD service. It was agreed that a development group be formed to develop the pathways further. Dr Dev Devapriya (Stockport FT) offered to lead this group and invites will be sent out via GM Chief Pharmacists and CCG leads.

Action: MM to email invitation to join the COPD and asthma pathway group to CPs and CCG leads for dissemination locally by 12th Oct

Item 7- DNP and Grey list

a – Additions to the DNP and Grey list were agreed as per item 5 above.

8 – Work-plan

The group considered the draft work plan and suggested amendments which have been incorporated into the version.

The group discussed possible changes to the workings of the subgroups, however these will be finalised following the meeting of the Chairs of the subgroups in November.

Action: No further action

9 – Additional feedback from GMMMG/NTS/IPS

The group were updated on any necessary information from the other GM subgroups.

10 – AOB

The NW pain group have invited a member from FSG to attend their meetings. SJ is unavailable to attend the next meeting however will ask Andrew Martin if he is able to attend.

Date of next meeting: Thursday 5th November 2015 – virtual meeting by email.